Polyoxometalate complexes and pharmaceutical compositions

Patent metadata

Field	Value
Publication number	US-12257225-B2
Application number	US-202217744369-A
Country	US
Kind code	B2
Filing date	May 13, 2022
Priority date	Oct 26, 2016
Publication date	Mar 25, 2025
Grant date	Mar 25, 2025

Abstract

The disclosure relates polyoxometalate complexes and uses in the management, treatment, or prevention of cancer. In certain embodiments, the polyoxometalate complexes comprise polydentate oxygen bridging ligands such as those of the following formula: [POM{(OCH 2 ) 3 CX} 2 ], [M 6 O 13 {(OCH 2 ) 3 CX} 2 ], [V 6 O 13 {(OCH 2 ) 3 CX} 2 ], salts, or derivatives thereof wherein POM is a polyoxometalate, M is a metal, and X is defined herein. In certain embodiments, the disclosure relates to pharmaceutical compositions comprising polyoxometalate complexes disclosed herein.

First claim

What is claimed is:

1. A pharmaceutical composition in the form of a pill, capsule, tablet, bead, granule, or micronized particle comprising [V 6 O 13 {(OCH 2 ) 3 CNH 3 } 2 ] zwitterionic salt and a pharmaceutically acceptable excipient.

2. The pharmaceutical composition of claim 1 , wherein the pill, capsule, tablet, bead, granule, or micronized particle comprises an enteric coating.

3. The pharmaceutical composition of claim 1 , wherein the pharmaceutically acceptable excipient is a diluent, binder, lubricant, disintegrant, colorant, stabilizer, or surfactant.

4. The pharmaceutical composition of claim 1 , wherein the pharmaceutically acceptable excipient is selected from a polyethylene glycol, propylene glycol, saccharide, polysaccharide, sucrose, lactose, sorbic acid, starch, talc, cellulose, microcrystalline cellulose, a cellulose ether, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, methyl cellulose, croscarmellose sodium, carboxymethylcellulose, xylitol, sorbitol, maltitol, and mannitol.

5. The pharmaceutical composition of claim 1 , wherein the pharmaceutically acceptable excipient is selected from a calcium salt, calcium phosphate, silicone dioxide, iron oxide, magnesium oxide, titanium dioxide, sodium lauryl sulfate, calcium stearate, magnesium stearate, and stearic acid or salt thereof.

6. The pharmaceutical composition of claim 1 , wherein the pharmaceutically acceptable excipient is selected from gelatin, crospovidone, povidone, and a paraben.

7. A pharmaceutical composition in the form of an aqueous solution comprising [V 6 O 13 {(OCH 2 ) 3 CNH 3 } 2 ] zwitterionic salt and a buffering agent.

8. The pharmaceutical composition of claim 7 , wherein the buffering agent provides a phosphate buffer solution.

9. The pharmaceutical composition of claim 7 , wherein the buffering agent provides a pH between 6 and 8.

10. The pharmaceutical composition of claim 7 , further comprising a salt.

11. The pharmaceutical composition of claim 10 , wherein the salt provides isotonic saline.

12. The pharmaceutical composition of claim 7 , further comprising a saccharide or polysaccharide.

13. The pharmaceutical composition of claim 7 , further comprising an antibacterial agent or antifungal agent.

14. The pharmaceutical composition of claim 7 , further comprising a paraben, chlorobutanol, phenol, or sorbic acid.

Assignees

• Univ Emory

Inventors

• Song Jie
• Nie Shuming
• Hill Craig

Classifications

• C09D5/02

  Emulsion paints {including aerosols} · CPC title

• C09D5/08

  Anti-corrosive paints · CPC title

• C09D7/65

  macromolecular (C09D7/41-C09D7/48 take precedence) · CPC title

• B32B21/02

  the layer being formed} of fibres, chips, or particles {, e.g. MDF, HDF, OSB, chipboard, particle board, hardboard · CPC title

• C07C229/00

  Compounds containing amino and carboxyl groups bound to the same carbon skeleton · CPC title